Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer

TAKAAKI MASUDA; YOSHIAKI SHINDEN; MIWA NODA; HIROKI UEO; QINGJIANG HU; YUKIHIRO YOSHIKAWA; YUSUKE TSURUDA; YOSUKE KURODA; SHUHEI ITO; HIDETOSHI EGUCHI; SHINJI OHNO; KOSHI MIMORI

doi:10.21873/anticanres.12755

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
Heatmap of exosomal miR profiles in serum from breast cancer patients with and without recurrence. The expression levels of these miRs range from low (green) to high (red). Patients 75, 83, 60, 95 and 94 had recurrence and patients 14, 7, 40, 35 and 25 had no recurrence.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Pre-miR-488 expression in breast cancer. A. The sequence of human pre-miR-488. The sequences in boldface are miR-488-5p and miR-488-3p. Underlined sequences are paired primers for PCR to detect pre-miR-488. B. Pre-miR-488 expression in blood samples from breast cancer patients. C. Pre-miR-488 expression in tissues of breast cancer patients. red: tumor tissues; blue: normal tissues. D. Pre-miR-488 expression in 3 blood fractions of breast cancer patients. The expression level in plasma is defined as follows: [putative plasma]=[whole blood]-[PMN]-[PBMC]-[RED]. E. Pre-miR-488 expression in the plasma of breast cancer patients. F. Correlation between pre-miR-488 and miR-488-5p expression in blood of breast cancer patients. r=0.457, p=0.017, Spearman's rank correlation co-efficient.
Download figure
Open in new tab
Download powerpoint
Figure 3.
Kaplan–Meier survival curve of breast cancer patients according to pre-miR-488 expression level to in blood. A. RFS. B. OS. C. Subgroup analysis for RFS of patients according to the status of HR and HER2. HR: Hormone receptor; TN: triple (ER, PgR, HER2) negative.